Craig Tim J, Shimomura Kenju, Holl Reinhard W, Flanagan Sarah E, Ellard Sian, Ashcroft Frances M
Henry Wellcome Centre for Gene Function, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, United Kingdom.
J Clin Endocrinol Metab. 2009 Jul;94(7):2551-7. doi: 10.1210/jc.2009-0159. Epub 2009 Apr 7.
Activating mutations in genes encoding the Kir6.2 (KCNJ11) and SUR1 (ABCC8) subunits of the pancreatic ATP-sensitive K(+) channel are a common cause of permanent neonatal diabetes (PNDM). All Kir6.2 mutations identified to date are missense mutations. We describe here a novel in-frame deletion (residues 28-32) in Kir6.2 in a heterozygous patient with PNDM without neurological problems that are detectable by standard evaluation.
The aim of the study was to identify the mutation responsible for neonatal diabetes in this patient and characterize its functional effects.
Wild-type and mutant Kir6.2/SUR1 channels were examined by heterologous expression in Xenopus oocytes.
The Kir6.2-28Delta32 mutation produced a significant decrease in ATP inhibition and an increase in whole-cell K(ATP) currents, explaining the diabetes of the patient. Tolbutamide block was only slightly reduced in the simulated heterozygous state, suggesting that the patient should respond to sulfonylurea therapy. The mutation decreased ATP inhibition indirectly, by increasing the intrinsic (unliganded) channel open probability. Neither effect was observed when Kir6.2 was expressed in the absence of SUR1, suggesting that the mutation impairs coupling between SUR1 and Kir6.2. Coimmunoprecipitation studies further revealed that the mutation disrupted a physical interaction between Kir6.2 and residues 1-288 (but not residues 1-196) of SUR1.
We report a novel KCNJ11 mutation causing PNDM. Our results show that residues 28-32 in the N terminus of Kir6.2 interact both physically and functionally with SUR1 and suggest that residues 196-288 of SUR1 are important in this interaction.
编码胰腺ATP敏感性钾通道Kir6.2(KCNJ11)和SUR1(ABCC8)亚基的基因发生激活突变是永久性新生儿糖尿病(PNDM)的常见病因。迄今鉴定出的所有Kir6.2突变均为错义突变。我们在此描述了一名患有PNDM的杂合子患者,其Kir6.2基因存在一种新的框内缺失(第28 - 32位氨基酸残基),且无标准评估可检测到的神经问题。
本研究旨在鉴定该患者新生儿糖尿病的致病突变并表征其功能效应。
通过在非洲爪蟾卵母细胞中进行异源表达来检测野生型和突变型Kir6.2/SUR1通道。
Kir6.2 - 28Delta32突变导致ATP抑制作用显著降低,全细胞KATP电流增加,这解释了该患者患糖尿病的原因。在模拟杂合状态下,甲苯磺丁脲阻断作用仅略有降低,提示该患者应能对磺脲类药物治疗产生反应。该突变通过增加内在(未结合配体)通道开放概率间接降低了ATP抑制作用。当Kir6.2在无SUR1的情况下表达时,未观察到上述任何一种效应,提示该突变损害了SUR1与Kir6.2之间的偶联。免疫共沉淀研究进一步表明该突变破坏了Kir6.2与SUR1第1 - 288位氨基酸残基(而非第1 - 196位氨基酸残基)之间的物理相互作用。
我们报道了一种导致PNDM的新型KCNJ11突变。我们的结果表明,Kir6.2 N端的第28 - 32位氨基酸残基在物理和功能上均与SUR1相互作用,并提示SUR1的第196 - 288位氨基酸残基在这种相互作用中很重要。